Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128906 · ClinicalTrials.gov registry record · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
A Phase 2 study of Squamous Cell Carcinoma, sponsored by Christopher Wilke.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02128906 is a Phase 2 study of Squamous Cell Carcinoma that is actively recruiting participants, run by Christopher Wilke. The registered enrollment target is 120 participants, above the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02128906, a Phase 2 study of Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Christopher Wilke.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC). The side effects of these combinations will also be studied. This study treatment consists of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. For study chemotherapy, patients will be randomized between cisplatin or the combination of docetaxel and cetuximab. Subjects will be stratified depending on HPV status and the presence of ERCC-1 \[4F9\] in the tumor prior to randomization. The study will evaluate cisplatin vs. docetaxel-cetuximab in the overall population, and test which radiation and chemotherapy combination works best in relationship to how much ERCC-1 \[4F9\] is expressed in a tumor.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Cetuximab
- RADIATION IMRT
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Radiation Oncology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2013-12-23 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128906
The ClinicalTrials.gov registry entry for NCT02128906 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (18% higher). The listed sponsor is Christopher Wilke, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT02128906 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02128906 about?
NCT02128906 is a clinical study titled "Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design". The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC). The side effects of these combinations will also be studied. This study treatment consists of intensity-modulated rad...
What is the current status of trial NCT02128906?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2013-12-23. Estimated completion is 2030-12.
What conditions does trial NCT02128906 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma.
What interventions are being tested in trial NCT02128906?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Cetuximab (DRUG), IMRT (RADIATION).
Who is sponsoring clinical trial NCT02128906?
This trial is sponsored by Christopher Wilke, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02128906 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.